Clinical Trial

CASCADE 2002: PROTECT Study, "PRObiotics to TrEat Anal preCancer Trial

Not Yet Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
This study is focused on treatment of anal high-grade squamous intraepithelial lesions (HSIL) in persons with HIV (PWH), with the ultimate goal of applying the approach toward prevention of anal cancer in this population
Protocol Amendment History 4 changes
notable Primary completion pushed: 2027-04-30 -> 2027-05-31 2026-07-16
minor Completion pushed: 2027-05-31 -> 2027-07-31 2026-07-16
notable Primary completion pushed: 2026-12-31 -> 2027-04-30 2026-05-02
minor Completion pushed: 2026-12-31 -> 2027-05-31 2026-05-02
Trial Details
NCT Number NCT06949800
Lead Sponsor University of California, San Francisco
Collaborators: Exegi Pharma, LLC, National Cancer Institute (NCI)
Conditions HSIL, High Grade Squamous Intraepithelial Lesion, HPV-Related Squamous Cell Carcinoma, Anal HSIL
Enrollment 90 participants
Start Date 2026-09-01
Primary Completion 2027-05-31 (estimated)
Study Completion 2027-07-31 (estimated)
Updated on ClinicalTrials.gov 2026-07-15